Hemispherx BioPharma shares declined 16 percent on nearly 6 million shares traded Tuesday. The company has reported that the FDA has declined to approve its new drug application for Ampligen for Chronic Fatigue Syndrome.
Going forward ... (see research report)
Copyright ® 2016. The Bedford Report. All Rights Reserved.